An anomaly in the field is the discrepancies between values often quoted for RAS mutations ranging from 15 to 30% of all cancers harbouring a RAS mutation and 60 to 98% of pancreatic cancers harbouring KRAS mutations [3,5]. This evidence concerns the gene KRAS and cancer.